The record
'Interpretation of the IARC quantitative bias analysis of talc and ovarian cancer' (Glob Epidemiol 2026, PMID 41658396) argues IARC's own quantitative bias analysis undercuts the ovarian-cancer conclusion: 'the QBA clearly showed that cohort study results were very similar before and after adjustment.'
Claim scope
That a peer-reviewed analysis of IARC's own quantitative bias analysis is part of the live dispute over the 2024 Group 2A upgrade.
What this source does not establish
Does NOT establish that IARC is wrong. These are critical commentaries and letters, not cohort studies; none supplies a new quantitative risk measure. Several are Critical Reviews in Toxicology papers of the kind commonly authored by consultants engaged in litigation — funding and competing-interest statements were not verified and must be flagged before publication.
Limitations
Represent both directions. On the other side of the same dispute: PMID 38995135 (Epidemiol Prev 2024) systematically reviewed the post-2006 epidemiology of asbestos-free talc. Do NOT present the critics as the consensus, and do NOT suppress them. Competing interests unverified — flag before publication.
Source
Pmid — 41658396